MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Thermo Fisher Scientific Inc

Затворен

СекторЗдравеопазване

489.21 1.42

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

480.45

Максимум

491.12

Ключови измерители

By Trading Economics

Приходи

194M

1.8B

Продажби

795M

11B

P/E

Средно за сектора

30.121

63.778

EPS

6.1

Дивидентна доходност

0.35

Марж на печалбата

16.007

Служители

125,000

EBITDA

377M

3B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+38.06% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.35%

2.39%

Следващи печалби

23.04.2025 г.

Следваща дата на дивидент

15.04.2025 г.

Следваща дата на екс-дивидент

13.06.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-40B

189B

Предишно отваряне

487.79

Предишно затваряне

489.21

Настроения в новините

By Acuity

33%

67%

106 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Thermo Fisher Scientific Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.02.2025 г., 14:05 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific to Acquire Solventum's Filtration Unit, Confirming WSJ Report

30.01.2025 г., 11:43 ч. UTC

Печалби

Thermo Fisher Scientific Profit, Revenue Rose in 4Q

23.10.2024 г., 10:43 ч. UTC

Печалби

Thermo Fisher Raises Floor of Earnings Target After Steady 3Q Sales

25.02.2025 г., 14:09 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Strikes Deal for Solventum's Filtration Unit -- WSJ

25.02.2025 г., 13:41 ч. UTC

Придобивния, сливания и поглъщания

Solventum: Transaction Is Expected to Be Completed by End of 2025 >SOLV

25.02.2025 г., 13:40 ч. UTC

Придобивния, сливания и поглъщания

Solventum Expects Estimated $3.4 B in Net Proceeds >SOLV

25.02.2025 г., 13:40 ч. UTC

Придобивния, сливания и поглъщания

Solventum: Deal Strengthens Balance Sheet With Proceeds to Be Used Primarily for Debt Paydown >SOLV

25.02.2025 г., 13:40 ч. UTC

Придобивния, сливания и поглъщания

Solventum Expects Deal to Be Neutral to 2025 EPS >SOLV

25.02.2025 г., 13:40 ч. UTC

Придобивния, сливания и поглъщания

Solventum: Deal Accelerates Business Transformation and Sharpens Focus on Strategic Areas for Growth

25.02.2025 г., 13:39 ч. UTC

Придобивния, сливания и поглъщания

Solventum Announces Sale of Its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

25.02.2025 г., 13:33 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher: Solventum Business Generated About $1 Billion Revenue in 2024 >TMO

25.02.2025 г., 13:32 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher to Buy Solventum Purification, Filtration Business for About $4.1 Billion Cash >TMO SOLV

25.02.2025 г., 13:32 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific To Acquire Solventum's Purification And Filtration Business >TMO

24.02.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific Nears Deal for Solventum's Purification and Filtration Business, Sources Say -- WSJ

24.02.2025 г., 23:03 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Thermo Fisher Nears Deal for Solventum Filtration Unit -- WSJ

24.02.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Deal Could be Announced This Week, Sources Say -- WSJ

24.02.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Transaction Could Value Solventum Filtration Business Between $3.5B to $4B, Sources Say -- WSJ

30.01.2025 г., 11:06 ч. UTC

Печалби

Thermo Fisher: In a Great Position to Deliver Excellent Performance in 2025 >TMO

30.01.2025 г., 11:05 ч. UTC

Печалби

Thermo Fisher: Will Provide 2025 Fincl Guidance During Earnings Conference Call Thursday Morning >TMO

30.01.2025 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Rev $11.4B >TMO

30.01.2025 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q EPS $4.78 >TMO

30.01.2025 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Core Organic Revenue Up 5% >TMO

30.01.2025 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Net $1.83B >TMO

30.01.2025 г., 11:00 ч. UTC

Печалби

Thermo Fisher 4Q Adj EPS $6.10 >TMO

16.12.2024 г., 22:03 ч. UTC

Топ новини

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

23.10.2024 г., 10:02 ч. UTC

Печалби

Thermo Fisher Had Seen 2024 Adjusted EPS $21.29-$22.07 >TMO

23.10.2024 г., 10:02 ч. UTC

Печалби

Thermo Fisher Backs 2024 View of Rev $42.4B-$43.3B >TMO

23.10.2024 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Core Organic Revenue 0% >TMO

23.10.2024 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q EPS $4.25 >TMO

23.10.2024 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Adj EPS $5.28 >TMO

Сравнение с други в отрасъла

Ценова промяна

Thermo Fisher Scientific Inc Прогноза

Ценова цел

By TipRanks

38.06% нагоре

12-месечна прогноза

Среден 666.81 USD  38.06%

Висок 715 USD

Нисък 570 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Thermo Fisher Scientific Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

14

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 513.14Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

106 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar